Addex Therapeutics (NASDAQ:ADXN) Downgraded to Hold at Zacks Investment Research
Zacks Investment Research cut shares of Addex Therapeutics (NASDAQ:ADXN – Get Rating) from a buy rating to a hold rating in a report issued on Monday morning, Zacks.com reports. According to Zacks, “Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. […]